Achieve Life Sciences, Inc. (ACHV)

Achieve Life Sciences, Inc. (NASDAQ: ACHV - Get Free Report) shares passed above its two hundred day moving average during trading on Thursday. The stock has a two hundred day moving average of $3.44 and traded as high as $4.82. Achieve Life Sciences shares last traded at $4.69, with a volume of 391,516 shares. Wall

SEATTLE and VANCOUVER, British Columbia, Dec. 08, 2025 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage specialty pharmaceutical company focused on the global development and commercialization of cytisinicline as a treatment of nicotine dependence, today announced that the company has issued inducement grants of stock options to Erik Atkisson, Chief Legal Officer, and other new employees.

Carisma Therapeutics (NASDAQ: CARM - Get Free Report) and Achieve Life Sciences (NASDAQ: ACHV - Get Free Report) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their dividends, analyst recommendations, earnings, profitability, valuation, institutional ownership and risk. Analyst Recommendations This is a breakdown

Achieve Life Sciences, Inc. (NASDAQ: ACHV - Get Free Report) crossed above its 200-day moving average during trading on Wednesday. The stock has a 200-day moving average of $3.24 and traded as high as $4.45. Achieve Life Sciences shares last traded at $4.32, with a volume of 390,366 shares. Analyst Upgrades and Downgrades ACHV has

Achieve Life Sciences, Inc. ( ACHV ) Q3 2025 Earnings Call November 6, 2025 8:30 AM EST Company Participants Nicole Jones Richard A. Stewart - CEO & Executive Director Jaime Xinos - Chief Commercial Officer Mark Oki - Chief Financial Officer Jerry Wan - VP of Finance & Principal Accounting Officer Conference Call Participants Thomas Flaten - Lake Street Capital Markets, LLC, Research Division Gary Nachman - Raymond James & Associates, Inc., Research Division Brandon Folkes - H.C.

One of Only Nine Therapies Chosen for the Inaugural FDA Commissioner's National Priority Voucher for E-cigarette or Vaping Cessation Conference Call Scheduled for 8:30 AM EST Today, November 6, 2025

120-Day Safety Update Submitted to FDA ORCA-OL Long-Term Safety Trial Successfully Concluded DSMC Completes Final Review of Cytisinicline, Finds No Drug Safety Concerns

SEATTLE and VANCOUVER, British Columbia, Oct. 29, 2025 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage specialty pharmaceutical company focused on the global development and commercialization of cytisinicline as a treatment of nicotine dependence for smoking cessation, today announced it will report its third quarter 2025 financial results and provide a corporate update on the cytisinicline development program on Thursday, November 6, 2025, at 8:30 AM EST.

New life sciences executive brings more than 25 years of legal expertise spanning clinical and commercial stage biopharmaceutical companies New life sciences executive brings more than 25 years of legal expertise spanning clinical and commercial stage biopharmaceutical companies

Achieve Life Sciences maintains its 'Buy' rating as the FDA accepts the NDA for cytisinicline for smoking cessation, with a PDUFA date set for June 20, 2026. ACHV's expansion into e-cigarette and vaping cessation is promising, supported by positive Phase 2 ORCA-V1 results and a Commissioner's National Priority Voucher from the FDA. Cytisinicline demonstrated a 2.6x higher quit rate vs. placebo in vaping cessation, and the FDA confirmed that a Phase 3 trial, plus ORCA-V1, could support an sNDA.

Potential First-in-Class Treatment for Nicotine E-cigarette or Vaping Cessation Receives Unprecedented Expedited Review Pathway

SEATTLE and VANCOUVER, British Columbia, Oct. 02, 2025 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage specialty pharmaceutical company focused on the global development and commercialization of cytisinicline for treatment of nicotine dependence for smoking cessation, today announced that effective October 1, 2025, Achieve's board of directors approved stock option grants to purchase an aggregate of 161,000 shares of its common stock for five new employees under Achieve's 2024 Equity Inducement Plan.

New data address critical treatment gap for millions of Americans with COPD who face unique smoking cessation challenges New data address critical treatment gap for millions of Americans with COPD who face unique smoking cessation challenges

Donnelly brings more than 25 years of biopharmaceutical expertise in CMC and regulatory operations Donnelly brings more than 25 years of biopharmaceutical expertise in CMC and regulatory operations

SEATTLE and VANCOUVER, British Columbia, Sept. 11, 2025 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage specialty pharmaceutical company focused on the global development and commercialization of cytisinicline for treatment of nicotine dependence for smoking cessation, today announced Mark Rubinstein, M.D., will assume the role of Interim Chief Medical Officer (CMO). Dr. Rubinstein will succeed Cindy Jacobs, Ph.D., M.D., who we anticipate will provide advisory services to support the company's ongoing efforts to advance cytisinicline as a potential treatment option for nicotine dependence.

Filing based on pivotal Phase 3 ORCA-2 and ORCA-3 clinical trials demonstrating statistically significant and clinically meaningful smoking cessation FDA acceptance starts the review process and sets timing for potentially the first new FDA-approved pharmacotherapy in two decades PDUFA targeted date set for June 20, 2026 SEATTLE and VANCOUVER, British Columbia, Sept. 03, 2025 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage specialty pharmaceutical company focused on the global development and commercialization of cytisinicline for treatment of nicotine dependence, today announced that the U.S. Food and Drug Administration (FDA) has accepted the cytisinicline New Drug Application (NDA) for a new treatment for smoking cessation in adults.